UA72519C2 - MONO- AND DISUBSTITUTED 3-PROPYL-g-AMINOBUTYRIC ACIDS - Google Patents

MONO- AND DISUBSTITUTED 3-PROPYL-g-AMINOBUTYRIC ACIDS Download PDF

Info

Publication number
UA72519C2
UA72519C2 UA2001128283A UA2001128283A UA72519C2 UA 72519 C2 UA72519 C2 UA 72519C2 UA 2001128283 A UA2001128283 A UA 2001128283A UA 2001128283 A UA2001128283 A UA 2001128283A UA 72519 C2 UA72519 C2 UA 72519C2
Authority
UA
Ukraine
Prior art keywords
aminomethyl
acid
methyl
methylheptanoic
hexanoic
Prior art date
Application number
UA2001128283A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of UA72519C2 publication Critical patent/UA72519C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/20—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/30—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/32—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UA2001128283A 1999-06-10 2000-05-31 MONO- AND DISUBSTITUTED 3-PROPYL-g-AMINOBUTYRIC ACIDS UA72519C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13848599P 1999-06-10 1999-06-10
PCT/US2000/015070 WO2000076958A2 (en) 1999-06-10 2000-05-31 Mono- and disubstituted 3-propyl gamma-aminobutyric acids

Publications (1)

Publication Number Publication Date
UA72519C2 true UA72519C2 (en) 2005-03-15

Family

ID=22482232

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2001128283A UA72519C2 (en) 1999-06-10 2000-05-31 MONO- AND DISUBSTITUTED 3-PROPYL-g-AMINOBUTYRIC ACIDS

Country Status (43)

Country Link
EP (1) EP1192125B9 (et)
JP (1) JP3904452B2 (et)
KR (1) KR100694735B1 (et)
CN (2) CN1196671C (et)
AP (1) AP1397A (et)
AR (1) AR033335A1 (et)
AT (1) ATE419231T1 (et)
AU (1) AU776723C (et)
BG (1) BG65561B1 (et)
BR (1) BR0011727A (et)
CA (2) CA2689997A1 (et)
CO (1) CO5200791A1 (et)
CR (1) CR6529A (et)
CU (1) CU23101A3 (et)
CY (1) CY1108827T1 (et)
CZ (2) CZ300834B6 (et)
DE (1) DE60041256D1 (et)
DK (1) DK1192125T3 (et)
DZ (1) DZ3253A1 (et)
EA (1) EA004398B1 (et)
EE (1) EE200100672A (et)
ES (1) ES2317839T3 (et)
GE (1) GEP20074142B (et)
HK (2) HK1046401B (et)
HR (1) HRP20020025A2 (et)
HU (1) HUP0201601A3 (et)
IL (2) IL146969A0 (et)
IS (1) IS6181A (et)
MA (1) MA26804A1 (et)
ME (1) MEP44808A (et)
MX (1) MXPA01012319A (et)
NO (2) NO327746B1 (et)
NZ (1) NZ515668A (et)
OA (1) OA11962A (et)
PE (1) PE20010285A1 (et)
PT (1) PT1192125E (et)
RS (2) RS50352B (et)
SI (1) SI1192125T1 (et)
SK (2) SK287247B6 (et)
TR (1) TR200103587T2 (et)
UA (1) UA72519C2 (et)
WO (1) WO2000076958A2 (et)
ZA (1) ZA200109711B (et)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
US6620829B2 (en) * 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
AU2002345664C1 (en) * 2001-06-11 2008-03-06 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
ITMI20011308A1 (it) 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
IL162028A0 (en) 2002-01-31 2005-11-20 Warner Lambert Co Alpha 2 delta ligands to treat tinnitus
NI200300043A (es) 2002-03-28 2003-11-05 Warner Lambert Co AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
US20030225149A1 (en) * 2002-04-30 2003-12-04 Blazecka Peter G. Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids
US7071339B2 (en) 2002-08-29 2006-07-04 Warner Lambert Company Llc Process for preparing functionalized γ-butyrolactones from mucohalic acid
NZ540591A (en) 2002-12-13 2008-03-28 Warner Lambert Co Pregabalin derivatives for the treatment of fibromyalgia and other disorders
EP1572187A1 (en) * 2002-12-13 2005-09-14 Warner-Lambert Company LLC Pregabalin and derivatives thereof for the treatment of fibromyalgia and other related disorders
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
JP2006511606A (ja) 2002-12-13 2006-04-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 下部尿路症状を治療するα−２−δリガンド
ITMI20022658A1 (it) 2002-12-17 2004-06-18 Nicox Sa Farmaci per il dolore cronico.
WO2005002585A1 (en) * 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
AU2004271800A1 (en) 2003-09-12 2005-03-24 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
CA2540247C (en) 2003-09-25 2011-01-25 Warner-Lambert Company Llc Prodrugs of amino acids with affinity for the .alpha.2.delta.-protein
JP4001349B2 (ja) * 2003-09-25 2007-10-31 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー α２δ−タンパク質に親和性を有するアミノ酸
WO2006043171A2 (en) * 2004-10-23 2006-04-27 Warner-Lambert Company Llc Methods of using alpha2delta-1 selective compounds
MY143249A (en) * 2005-09-15 2011-04-15 Ucb Pharma Sa 4-substituted pyrrolidin-2-ones and their use
US20070141684A1 (en) 2005-12-21 2007-06-21 Pfizer Inc Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
RS51940B (en) 2006-12-22 2012-02-29 Recordati Ireland Limited Combined TH2δ LIGANAD THERAPY AND NSAID FOR LOWER URINARY TRACT DISORDERS
WO2009136375A1 (en) * 2008-05-08 2009-11-12 Pfizer Inc Treatment of interstitial cystitis
JP5815552B2 (ja) 2009-12-08 2015-11-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 眼疾患を治療する化合物および方法
CN101914031B (zh) * 2010-07-30 2013-08-28 中国广州分析测试中心 普瑞巴林衍生物及其应用
CA3234750A1 (en) * 2015-10-23 2017-04-27 Navitor Pharmaceuticals, Inc. Modulators of sestrin-gator2 interaction and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
AU9137091A (en) * 1990-11-27 1992-06-25 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
RU94046105A (ru) * 1992-05-20 1997-06-20 Нортвестерн Юниверсити (Us) АНАЛОГИ γ -АМИНОМАСЛЯНОЙ КИСЛОТЫ И L-ГЛУТАМИНОВОЙ КИСЛОТЫ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
US5637767A (en) * 1995-06-07 1997-06-10 Warner-Lambert Company Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
KR100491282B1 (ko) * 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
EP0937032B1 (en) * 1996-10-23 2007-05-09 Warner-Lambert Company LLC Substituted gamma aminobutyric acids as pharmaceutical agents
BR9813284B1 (pt) * 1997-10-27 2012-08-21 aminoácidos cìclicos e derivados dos mesmos úteis como agentes farmacêuticos e composição farmacêutica.

Also Published As

Publication number Publication date
NO20091094L (no) 2001-12-05
AP2002002388A0 (en) 2002-03-31
HUP0201601A3 (en) 2002-11-28
NZ515668A (en) 2004-02-27
GEP20074142B (en) 2007-07-10
IL146969A (en) 2008-03-20
EE200100672A (et) 2003-02-17
MA26804A1 (fr) 2004-12-20
YU87001A (sh) 2004-07-15
CN1310872C (zh) 2007-04-18
CN1196671C (zh) 2005-04-13
TR200103587T2 (tr) 2002-04-22
DZ3253A1 (fr) 2000-12-21
OA11962A (en) 2006-04-17
HK1046401B (zh) 2005-12-02
MEP44808A (en) 2011-02-10
EP1192125B1 (en) 2008-12-31
RS50352B (sr) 2009-11-10
IS6181A (is) 2001-11-28
RS20090257A (en) 2010-03-02
MXPA01012319A (es) 2002-07-22
NO20015949L (no) 2001-12-05
NO20015949D0 (no) 2001-12-05
PE20010285A1 (es) 2001-03-22
NO327746B1 (no) 2009-09-14
JP2003502308A (ja) 2003-01-21
CA2374755C (en) 2010-03-30
CA2374755A1 (en) 2000-12-21
ES2317839T3 (es) 2009-05-01
BR0011727A (pt) 2002-03-05
KR20020009631A (ko) 2002-02-01
ATE419231T1 (de) 2009-01-15
EA004398B1 (ru) 2004-04-29
CZ301608B6 (cs) 2010-04-28
AU776723B2 (en) 2004-09-16
EA200101134A1 (ru) 2002-06-27
BG106292A (en) 2002-05-31
JP3904452B2 (ja) 2007-04-11
HK1046401A1 (en) 2003-01-10
DE60041256D1 (de) 2009-02-12
SK17642001A3 (sk) 2002-10-08
AP1397A (en) 2005-04-19
CY1108827T1 (el) 2014-04-09
AU5311900A (en) 2001-01-02
SK287399B6 (sk) 2010-08-09
AR033335A1 (es) 2003-12-17
ZA200109711B (en) 2003-03-20
CR6529A (es) 2003-11-25
WO2000076958A2 (en) 2000-12-21
HUP0201601A2 (en) 2002-10-28
SI1192125T1 (sl) 2009-04-30
BG65561B1 (bg) 2008-12-30
EP1192125B9 (en) 2009-09-16
HK1076626A1 (en) 2006-01-20
KR100694735B1 (ko) 2007-03-14
CN1660779A (zh) 2005-08-31
CU23101A3 (es) 2005-12-20
IL146969A0 (en) 2002-08-14
CZ20014285A3 (cs) 2002-07-17
CO5200791A1 (es) 2002-09-27
AU776723C (en) 2005-06-02
EP1192125A2 (en) 2002-04-03
DK1192125T3 (da) 2009-02-16
PL352431A1 (en) 2003-08-25
SK287247B6 (sk) 2010-04-07
PT1192125E (pt) 2009-03-05
WO2000076958A3 (en) 2001-04-12
CN1355784A (zh) 2002-06-26
CZ300834B6 (cs) 2009-08-19
CA2689997A1 (en) 2000-12-21
HRP20020025A2 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
UA72519C2 (en) MONO- AND DISUBSTITUTED 3-PROPYL-g-AMINOBUTYRIC ACIDS
AU2003208538B2 (en) Amino acids with affinity for the alpha-2-delta-protein
KR101739677B1 (ko) 페닐카바메이트 화합물 및 이를 포함하는 정신 질환의 예방 또는 치료용 조성물
US6642398B2 (en) Mono-and disubstituted 3-propyl gamma-aminobutyric acids
CN109939092B (zh) 用于预防或治疗小儿癫痫和癫痫相关综合征的苯基氨基甲酸酯化合物
WO2015101294A1 (zh) 镇痛活性化合物及其医药用途
CA2539976A1 (en) Therapeutic beta aminoacids
Shi et al. Design, Synthesis, and Preliminary Evaluation of Gabapentin‐Pregabalin Mutual Prodrugs in Relieving Neuropathic Pain
EP1840117A1 (en) Mono- and disubstituted 3-propyl gamma-aminobutyric acids
CN1673212A (zh) 加巴喷丁与普瑞巴林的互联体前药及其医药用途
OA12897A (en) Mono-and disubstituted 3-propyl gamma-aminobutyricacids.
PL203443B1 (pl) Monopodstawiony kwas 3-propylo- ?-aminomas lowy, kompozycja farmaceutyczna zawieraj aca ten zwi azek i zastosowanie